Business Context and Reporting Period
This Form 8-K Current Report was filed by C4 Therapeutics, Inc. on April 30, 2021, covering the event date of April 27, 2021. The company is a Delaware corporation with its principal executive offices in Watertown, MA, and its common stock trades on The Nasdaq Global Market under the symbol CCCC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The material change reported is the departure of a key executive officer:
- Resignation: Laura J. Wahlberg resigned as Vice President, Finance, Corporate Controller, and Principal Accounting Officer.
- Effective Date: The resignation is effective as of May 28, 2021.
- Transition: Ms. Wahlberg has agreed to provide transitional services following her departure under the terms of a consulting agreement.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document contains no unusual items or forward-looking statements regarding the company's business trajectory.
Key Facts for Investor Verification
- Verify the appointment of a new Corporate Controller and Principal Accounting Officer to ensure continuity in financial reporting.
- Confirm the terms of the consulting agreement regarding transitional services to assess potential costs.
- Monitor subsequent filings for any impact on the company's internal controls over financial reporting due to the leadership change.